GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
 - EconoTimes)
NEW YORK, Nov. 08, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against InfuSystem Holdings, Inc. (“InfuSystem” or the “Company”) (NYSE:INFU) in the United States District Court for the Central District of California on behalf of purchasers of common stock of InfuSystem between May 12, 2015 and November 7, 2016, inclusive (the “Class Period”).
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) InfuSystem lacked effective internal control over financial reporting; (2) InfuSystem’s financial statements dating back to the beginning of 2015 overstated the estimated accounts receivable collections which in turn overstated revenues and pre-tax income by a corresponding amount; (3) InfuSystem’s financial statements dating back to the beginning of 2015 could no longer be relied upon; and (4) as a result of the foregoing, the InfuSystem’s financial statements were materially false and misleading at all relevant times. When the true details entered the market, the Complaint alleges that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
